(Q39705884)

14 September 2017

Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells (English)

1 reference

14 September 2017

0 references

3

Ilaria Dicembrini

1 reference

14 September 2017

Laura Pala

1

1 reference

14 September 2017

Anna Pezzatini

2

1 reference

14 September 2017

Silvia Ciani

4

1 reference

14 September 2017

Stefania Gelmini

5

1 reference

14 September 2017

Barbara Gabriella Vannelli

6

1 reference

14 September 2017

Barbara Cresci

7

1 reference

14 September 2017

Edoardo Mannucci

8

1 reference

14 September 2017

Carlo Maria Rotella

9

1 reference

14 September 2017

language of work or name

1 reference

9 May 2010

1 reference

14 September 2017

1 reference

14 September 2017

49 Suppl 1

1 reference

14 September 2017

S59-63

1 reference

https://scigraph.springernature.com/pub.10.1007/s00592-010-0195-3

14 September 2017

0 references

cites work

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-010-0195-3

10.1007/S00592-010-0195-3

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference